Pharma IQ Members

Whitepapers

71 results
of 8
AI in Pharma
Drug development approaches a fascinating era as the trend of digitalization introduces sophisticated technologies which can neutralize the costly hazards faced in pharma’s R&D pipelines, according to a new deep-dive study by Pharma IQ
Tags:
Infographic pharma
Pharma IQ presents a few statistics gathered from the medical press on today’s drug discovery industry.
Tags: pharma, medicine, disease, pharmacy, health professional, health organization, drug, medical, ill, illness, drug discovery,
Biothumb
This white paper suggests an innovative R&D approach to deliver high quality products to market while reducing cost and improving ROI.
Tags:
Compound
Download this troubleshooting guide to explore the important aspects to consider with compound and biosample management IT issues.
Tags:
comp
Pharma IQ revisits the compound and biobanking markets to pinpoint any shifts or new trends in the market.
Tags:
CRISPR oc2
We spoke to CRISPR experts Robin Ketteler and Lorena Benedetti to find out about their work within CRISPR, insights on where the technique is heading and the field’s exciting developments.
Tags:
CRISPR Content
CRISPR is now one of the most affordable forms of gene editing causing a boom in R&D over the last few years. However, the technique does have its limitations which include maintaining end to end control on genetic manipulation, avoiding off targets effects and pathway recovery post double strand break.Ahead of the 2017 CRISPR summit Javier Read more
Tags:
Bio oc2
With the growth of biologics showing no signs of stopping, bioinformatics continues to be a key driver when it comes to R&D development. Ahead of this year's Lab Informatics Summit, Pharma IQ speaks to an array of experts on the subject of data knowledge management with complex datasets.
Tags:
lab info
Ahead of the Lab Informatics Summit, Pharma IQ presents a selection of considerations to assist labs on their route to full integration and interoperability.
Tags:
C&G OC3
The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.
Tags:
71 results
of 8